The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.

[1]  G. MacGowan,et al.  Iatrogenic pulmonary artery pseudoaneurysm: images from different modalities , 2008, Thorax.

[2]  F. Maltais,et al.  Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial , 2007, Thorax.

[3]  D. Postma,et al.  A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. , 2007, Chest.

[4]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[5]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[6]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[7]  D. Niewoehner.  The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. , 2006, The American journal of medicine.

[8]  R. Zuwallack,et al.  Functional status and quality of life in chronic obstructive pulmonary disease. , 2006, The American journal of medicine.

[9]  B. Celli,et al.  Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. , 2006, Chest.

[10]  T. Lasserson,et al.  Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.

[11]  Jasjit S Ahluwalia,et al.  Interventions to facilitate smoking cessation. , 2006, American family physician.

[12]  D. Roblin,et al.  Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. , 2006, Respiratory medicine.

[13]  I. Pavord,et al.  Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. , 2006, American journal of respiratory and critical care medicine.

[14]  D. Sin,et al.  Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. , 2006, European journal of pharmacology.

[15]  C. D. Mathers,et al.  Chronic obstructive pulmonary disease: current burden and future projections , 2006, European Respiratory Journal.

[16]  R. Stockley,et al.  Addition of salmeterol to existing treatment in patients with COPD: a 12 month study , 2006, Thorax.

[17]  S. Johnston,et al.  Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells. , 2006, American journal of respiratory cell and molecular biology.

[18]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[19]  D. Postma,et al.  Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease , 2005, Thorax.

[20]  G. Viegi,et al.  Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA. , 2005, Respiratory medicine.

[21]  N. Pride,et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. , 2005, American journal of respiratory and critical care medicine.

[22]  E. Wouters,et al.  Are patients with COPD psychologically distressed? , 2005, European Respiratory Journal.

[23]  A. Agustí,et al.  COPD, a multicomponent disease: implications for management. , 2005, Respiratory medicine.

[24]  D. Postma,et al.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.

[25]  K. Rascati,et al.  A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. , 2005, Clinical therapeutics.

[26]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[27]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[28]  J. Hogg,et al.  Pathophysiology of airflow limitation in chronic obstructive pulmonary disease , 2004, The Lancet.

[29]  R. Pauwels,et al.  Burden and clinical features of chronic obstructive pulmonary disease (COPD) , 2004, The Lancet.

[30]  T. Wilt,et al.  Effectiveness of statin therapy in adults with coronary heart disease. , 2004, Archives of internal medicine.

[31]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[32]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[33]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[34]  T. Lasserson,et al.  Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. , 2004, The Cochrane database of systematic reviews.

[35]  D. Au,et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. , 2003, American journal of respiratory and critical care medicine.

[36]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[37]  E. R. Sutherland,et al.  Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis , 2003, Thorax.

[38]  N. Hanania,et al.  The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .

[39]  S. Suissa.  Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. , 2003, American journal of respiratory and critical care medicine.

[40]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[41]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[42]  S. Man,et al.  Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? , 2003, European Respiratory Journal.

[43]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[44]  N. Pride,et al.  Inhaled Corticosteroids With/Without Long-Acting β-Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[45]  I. Adcock,et al.  Molecular interactions between glucocorticoids and long-acting β2-agonists , 2002 .

[46]  M. Roth,et al.  Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling , 2002, The Lancet.

[47]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[48]  N. Pride,et al.  Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice , 2002, European Respiratory Journal.

[49]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[50]  B. Beghé,et al.  Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. , 2002, American journal of respiratory and critical care medicine.

[51]  Abdullah Alsaeedi,et al.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. , 2002, The American journal of medicine.

[52]  A. Schols,et al.  Systemic effects in COPD. , 2002, Chest.

[53]  J. Tu,et al.  Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[54]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[55]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[56]  F. Martinez.  Surgical Therapy for Chronic Obstructive Pulmonary Disease: Conventional Bullectomy and Lung Volume Reduction Surgery in the Absence of Giant Bullae , 1999 .

[57]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[58]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[59]  Keith McNeil,et al.  International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). , 1998, American journal of respiratory and critical care medicine.

[60]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[61]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[62]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[63]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[64]  T. De,et al.  Parenteral nutrition before gastrointestinal surgery. , 1982 .